Plain-English translation of NCT06461377 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether semaglutide, a medication already used to help control blood sugar in type 2 diabetes, can also help repair nerve damage that affects the heart. Diabetic cardiac autonomic neuropathy is a serious complication of diabetes that can cause irregular heartbeat, dizziness, and other dangerous symptoms. Researchers want to see if this medication might prevent or improve this type of nerve damage.
Many people with type 2 diabetes develop nerve damage that affects how their heart works, and this can be life-threatening. While this medication is known to help with blood sugar control and other types of nerve damage, there is very little research on whether it can help protect the heart's nerves specifically.
You likely qualify if…
You likely don't qualify if…
You would receive either the new medication or standard diabetes care alone for 12 weeks. If you are in the treatment group, you would receive a subcutaneous injection (under the skin) of the medication once per week, with the dose adjusted based on your body weight. Throughout the study, your doctors will monitor your blood sugar, insulin resistance, and how well your heart nerves are functioning to see if the treatment helps.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment target
~50 participants
Started
June 2024
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
jianbo Li, MD/PhD
First Affiliated Hospital，Nanjing Medical University，China
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.